Shares up 125% on new drug data

Posted 30 January 2025 PM 

Shares in Alterity Therapeutics skyrocketed 125 per cent after the biotech released data showing its iron-targeting agent ATH434 significantly slowed progression of Multiple System Atrophy (MSA), a rare neurological disorder that has no cure or treatment.

The Melbourne-based company, formerly known as Prana Biotechnology, went into a trading halt on Tuesday ahead of releasing positive topline results from the ATH434-201 placebo-controlled Phase 2 clinical trial, which enrolled 77 adults with early-stage MSA across six countries.

To see the whole article, please login